Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RNable

Financiado

RNA and Nanotechnology Enable Wider Accessibility to Stem Cell Transplantation

Every year, more than 50 000 patients receive blood stem cell transplantation as a curative treatment for diseases such as leukemia, immune deficiencies, and sickle cell anemia. For a successful transplantation, a matching donor w... ver más

29/02/2024

LUNDS UNIVERSITET

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

LUNDS UNIVERSITET

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2015-200-C02-02 BIOMATERIALES Y NANOPARTICULAS PARA MEJORAR EL IMPLANTE CELU... 75K€ Cerrado

EnBioN Engineering the Biointerface of Nanowires to Direct Stem Cel... 1M€ Cerrado

SAF2015-72617-EXP REPROGRAMACION Y REGENERACION TISULAR A PARTIR DE MICROVESIC... 48K€ Cerrado

RTC-2016-5451-1 DESARROLLO DE SISTEMAS DE BIOIMPRESIÓN Y BIOTINTAS PARA REGE... 204K€ Cerrado

PGC2018-102047-B-I00 ANDAMIOS BIOHIBRIDOS ASOCIADOS CON APATITOS NANOCRISTALINOS... 133K€ Cerrado

EX-STENT THE NEXT STENT GENERATION: A FIRST-IN-CLASS REGENERATIVE NAN... 5M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-08-22
Fecha Fin: 2024-02-29

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Every year, more than 50 000 patients receive blood stem cell transplantation as a curative treatment for diseases such as leukemia, immune deficiencies, and sickle cell anemia. For a successful transplantation, a matching donor who is willing to donate blood stem cells needs to be found. Worldwide, around 30% patients in need of a transplantation cannot find a suitable donor. Umbilical cord blood (UCB) is an easily obtainable alternative source of blood stem cells, but unfortunately most UCB units do not contain enough stem cells for a successful transplantation, which is why UCB is currently only rarely used in the clinic. Within the ERC project UNEXPECTED, we have identified several small RNA biomolecules that can be used to expand engraftable blood stem cells efficiently. However, it is difficult to safely deliver molecules to blood stem cells, and currently used methods are highly toxic. We recently applied cutting edge nanotechnology to solve this long-standing problem in stem cell biology. We established nanostraws as an efficient and gentle alternative delivery method with which both cell function and viability are fully maintained. Our method that allows efficient non-toxic delivery of blood stem cell-expanding RNAs will allow us to greatly increase the number of UCB units that can be used for transplantations. Our approach could provide a life-saving treatment option for the thousands of patients yearly with malignant or inherited diseases that currently are ineligible for a stem cell transplantation procedure.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores